As a researcher of the MepAnti consortium, Bruna is responsible for virtual and fragment screenings for the second enzyme of the MEP pathway, DXR. The goal is to find new inhibitors for this target and pave the way for the drug discovery and development of new antibiotics. The interplay of theoretical and experimental methods is a key point to refine the validation of the potential inhibitors found.
MepAnti webpage: http://mepanti.hips-wordpress.helmholtz-hzi.de/
MepAnti is an Innovative Training Network (ITN) from the Marie Skłodowska-Curie Actions (MSCA) for Early Stage Researchers (ESRs), funded by the European Commission under the H2020 Program, the EU framework for research and innovation. Our aim is to discover and develop novel anti-infective agents targeting the attractive and underexplored enzymes from the MEP pathway, a precursor of molecules essential for the metabolism, structure and regulation of many human pathogens.
Bruna holds a BSc in Pharmacy (2018) and a MSc in Biosciences (2020), both at the Federal University of Health Sciences of Porto Alegre (UFCSPA), Brazil. She is currently a PhD candidate at the University of Bergen (UiB) in Norway and a member of Ruth Brenk's research group at the UiB's Biorecognition Unit.
Brenk's lab webpage: https://www.uib.no/en/rg/brenk